drugset
drugset / Trial / NCT04797000

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

NCT04797000 ↗

Phase 2 Active not recruiting 36 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).

Timeline

Start
2021-05-25
Primary completion
2025-04-26
Completion
2026-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 12.5 mg Oral
Subject Eltrombopag Small molecule 25 mg Oral

Indications

myelodysplastic syndrome